Jump to content

Search the Community

Showing results for tags 'Bone metastases'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • COMMUNITY
    • Announcements, meetings and other resources
  • ADVANCED PROSTATE CANCER FORUMS
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
  • MEMBER'S STORIES AND NEEDS
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Found 5 results

  1. Guest

    Lu177

    Hi All, My husband Terry was diagnosed with mCRPC in September 2016. After Brachytherapy he has tried various treatment which have all eventually failed, including Zytiga and Docetaxel. At present, he is having radiotherapy on the spine to prevent paraplegia. He has been told this morning from his oncologist that Lu177 may give him only 4-6 weeks. Has anyone had a similar diagnosis or experience they would be willing to share? Many thanks, look forward to hearing from you. Tricia (Terry's wife)
  2. Click here to read "A Brief Update of the Current Landscape of Bone Targeted Therapies for Prostate Cancer" by Joel Nowak of Malecare. Radium 223 (Xofigo) has been approved for use in Australia. However it is not publicly subsidised. This means that its cost effectively puts it out of reach of most Australian men with advanced prostate cancer. Your committee is lobbying to try to get Radium 223 (Xofigo) publicly subsidised. However it's unlikely to be publicly subsidised in the near future.
  3. The results of a large, randomized clinical trial of the use of zoledronic acid (Zometa) were presented at the recent annual meeting of the American Society of Clinical Oncology (ASCO). In this trial the researchers set out to test whether giving zoledronic acid every 3 months would be just as effective (i.e., “non-inferior”) at reducing bone pain and skeletal-related events (SREs) in patients with bone metastases as giving it according to the standard recommended regimen (once a month) specified in the product’s prescribing information. They found that zoledronic acid administered every 3 months was just as effective to zoledronic acid administered monthly for 24 months in breast cancer, prostate cancer and multiple myeloma patients. Dr Jeffrey J. Kirshner identified this trial as one of the 10 practice-changing presentations from this year's ASCO annual meeting and said this less frequent dosing of zoledronic acid “will be less expensive and result in fewer visits for our patients and probably an improved quality of life.” References (click on the link to read) Article in the “New” Prostate Cancer Infolink Abstract of the trial presented at ASCO Comments by Dr Kirshner
  4. Joel Nowak on the Malecare Advanced Prostate Cancer Blog reports on the results of a recent Swedish study. Click on this link to read about the study.
  5. More from this year's Annual General Meeting of the American Society of Clinical Oncologists (ASCO). Zometa (zoledronic acid), when given to men with bone metastases, has been shown to both delay damage to bones and to extend life. The current standard of care is to give to Zometa every 4 weeks. Research presented at the ASCO Annual Meeting gave the results of a trial which compared giving Zometa every 12 weeks with giving it every 4 weeks. The trial studied 1,822 patients (with three different diseases - Prostate Cancer, breast cancer and multiple myeloma) for a period of 2 years. The trial found that administering Zometa every 12 weeks was not inferior to administering it every 4 weeks. There were no significant differences in side effects between the 2 different dosing schedules. Zometa is given to the patient via an intravenous infusion. There are obvious benefits for the patient in only having to have the treatment every 12 weeks, instead of every 4 weeks. There is also the benefit that a 12 weekly dosing schedule is cheaper than a 4 weekly dosing schedule. It is likely that this research will lead to a change in the frequency of treatments for patients on Zometa. Reference: A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. http://meetinglibrary.asco.org/content/147845-156
×
×
  • Create New...